Clinical Trial Update: SPIRIT FIRST Clinical Trial of the Abbott Vascular XIENCE V® Everolimus Eluting Coronary Stent System [Phase 3]

View source ↗

Summary

Phase 3 clinical trial SPIRIT FIRST evaluating the XIENCE V Everolimus-eluting coronary stent system by Abbott has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Artery Stenosis
• Myocardial Ischemia
• Peripheral Vascular Disease

Drugs mentioned

• XIENCE V Everolimus Eluting Coronary Stent System (Everolimus-eluting coronary stent)

Snippet

Sponsor: Abbott Medical Devices | Conditions: Coronary Artery Disease, Everolimus | Phase 3 | Status: COMPLETED